BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 19790066)

  • 1. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.
    Varani K; Massara A; Vincenzi F; Tosi A; Padovan M; Trotta F; Borea PA
    Arthritis Rheum; 2009 Oct; 60(10):2880-91. PubMed ID: 19790066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role and Function of A
    Ravani A; Vincenzi F; Bortoluzzi A; Padovan M; Pasquini S; Gessi S; Merighi S; Borea PA; Govoni M; Varani K
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release.
    Varani K; Padovan M; Vincenzi F; Targa M; Trotta F; Govoni M; Borea PA
    Arthritis Res Ther; 2011; 13(6):R197. PubMed ID: 22146575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level.
    Madi L; Cohen S; Ochayin A; Bar-Yehuda S; Barer F; Fishman P
    J Rheumatol; 2007 Jan; 34(1):20-6. PubMed ID: 17216675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes.
    Meusch U; Rossol M; Baerwald C; Hauschildt S; Wagner U
    Arthritis Rheum; 2009 Sep; 60(9):2612-21. PubMed ID: 19714631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of adenosine A3 receptors controls adenosine A2A receptor-mediated inhibition of TLR responses in microglia.
    van der Putten C; Zuiderwijk-Sick EA; van Straalen L; de Geus ED; Boven LA; Kondova I; IJzerman AP; Bajramovic JJ
    J Immunol; 2009 Jun; 182(12):7603-12. PubMed ID: 19494284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adalimumab (Humira)--efficacy in rheumatoid arthritis treatment with particular reference to working ability].
    Grazio S
    Reumatizam; 2008; 55(2):62-7. PubMed ID: 19024278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease.
    Varani K; Vincenzi F; Tosi A; Gessi S; Casetta I; Granieri G; Fazio P; Leung E; MacLennan S; Granieri E; Borea PA
    FASEB J; 2010 Feb; 24(2):587-98. PubMed ID: 19776336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.
    Ochaion A; Bar-Yehuda S; Cohn S; Del Valle L; Perez-Liz G; Madi L; Barer F; Farbstein M; Fishman-Furman S; Reitblat T; Reitblat A; Amital H; Levi Y; Molad Y; Mader R; Tishler M; Langevitz P; Zabutti A; Fishman P
    Arthritis Res Ther; 2006; 8(6):R169. PubMed ID: 17101059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.
    Saiki O; Takao R; Naruse Y; Kuhara M; Imai S; Uda H
    J Rheumatol; 2007 Oct; 34(10):1997-2004. PubMed ID: 17787045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.